Lifeward Ltd. 8-K Filings

Lifeward Ltd. (LFWD) released an investor presentation outlining its strategy as a restorative healthcare platform focused on robotic exoskeletons and rehabilitation technologies, supported by what it describes as an established reimbursement infrastructure. The company reports last-twelve-month revenue of $21.8 million as of June 30, 2026 and $6.6 million in second-quarter 2026 revenue, up 15% year over year, with a 42% gross margin and a pro forma cash position of $10.9 million.

The presentation highlights a portfolio including the ReWalk powered exoskeleton, AlterG anti-gravity rehab systems, and an upper-extremity exoskeleton in development, plus a connected data platform and multiple pipeline products targeted for 2027–2031, each subject to regulatory clearance. Lifeward emphasizes reimbursement “moat” elements: HCPCS code K1007, an established Medicare Fee Schedule rate of $95,081, and estimated coverage for about 46% of Medicare Advantage enrollees. A strategic partnership with Oramed Pharmaceuticals could provide up to $47 million in milestone-based funding and gives Lifeward economic exposure to Oramed’s Protein Oral Delivery (POD) platform and oral insulin candidate ORMD-0801, while Oramed oversees development.

Lifeward Ltd. (LFWD) announced leadership changes effective in late 2026. On August 31, 2026, President and Chief Executive Officer Mark Grant departed his roles, including his Board seat, under a Separation Agreement. He will serve as Senior Advisor through September 30, 2026 for a $40,000 consulting fee, with all unvested equity awards forfeiting as of August 31, 2026 and no cash severance or extended benefits beyond accrued compensation.

The Board appointed Josh Hexter, age 56, as Interim Chief Executive Officer and principal executive officer effective September 1, 2026, under an employment agreement providing a gross monthly base salary of NIS 100,000 plus a NIS 5,000 commuting allowance or a company car and an annual bonus eligibility. Hexter will substantially reduce his responsibilities at controlling shareholder Oramed Pharmaceuticals Inc. The Board also appointed Rami Aviram, age 47, as Chief Financial Officer, principal financial officer and principal accounting officer effective November 1, 2026, with a gross monthly base salary of NIS 70,000 and a NIS 5,000 commuting allowance or a company car, along with customary Israeli-law benefits and bonus eligibility.

Lifeward Ltd. (LFWD) reported changes to its Board of Directors. On August 14, 2026, the Board appointed Yonason Greenwald and Haggai Zamir as Class III Directors, with initial terms expiring at the 2026 Annual Meeting of Shareholders. Mr. Greenwald will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees, and Mr. Zamir will serve on the Nominating and Corporate Governance Committee.

On August 20, 2026, the Board appointed Avraham Gabay as a Class III Director and Chair of the Board, also with a term expiring at the 2026 Annual Meeting. All three will receive the company’s standard non-employee director compensation. On the same date, Nadav Kidron resigned from the Board, effective immediately; the company states his departure did not result from any disagreement regarding operations, policies, or practices.

Lifeward Ltd. reported second quarter 2026 results showing higher revenue but a larger net loss, alongside significant leadership changes. Revenue increased 16% to $6.6 million from $5.7 million a year earlier, driven by ReWalk Personal exoskeleton sales of $2.5 million and AlterG products and services of $4.1 million. Gross margin was 41%, down from 44% due to higher tariffs, foreign exchange impacts and a 4% revenue-sharing expense tied to the Oramed transaction.

Total operating expenses declined 24% to $6.9 million, reflecting prior-year impairment charges, and operating loss improved 37% to $4.2 million. However, net loss widened to $11.5 million (or $4.12 per share) from $6.6 million, mainly from non-cash fair value charges on warrant and derivative liabilities. On a non-GAAP basis, net loss was $4.1 million. Cash and cash equivalents rose to $9.4 million as of June 30, 2026, versus $2.2 million at year-end 2025, with a pro forma balance of about $11 million including a July 2026 capital raise.

Governance changes include the resignations of directors Robert J. Marshall, Jr., Michael Swinford and William Mark Sigsbee, effective August 13, 2026, with no disagreements cited. Chief Financial Officer Almog Adar will step down effective September 30, 2026, under a separation agreement treated as a termination without cause while he supports the transition.

Lifeward Ltd. entered into a new financing arrangement built around senior secured convertible notes and warrants. The company closed an initial issuance of $5,580,000 in notes on July 6, 2026, with a second $5,580,000 tranche available upon meeting performance or share-price conditions.

Each note has a three-year term, carries 8.0% annual interest (rising to 15.0% on default) and is convertible into ordinary shares at an initial price of $5.40 per share. Investors also receive warrants exercisable for up to 100% of the shares underlying each note, also at $5.40 per share, immediately exercisable and expiring after five years. Both notes and warrants include a 4.99% beneficial ownership cap and a 19.99% exchange cap on total share issuance unless shareholders approve more. The securities were sold in a private offering to accredited investors under Rule 506(b) of Regulation D.

Lifeward Ltd. appointed Keith D. Rose, M.D. as its Chief Medical Officer, effective May 1, 2026. He has served in several senior medical affairs roles at the company since March 2023, most recently as Vice President, Medical Affairs, Medical Director – Neurosciences.

Before joining Lifeward, Dr. Rose held medical leadership positions at Biocodex, Novocure, Ipsen, Jazz Pharmaceuticals and Indivior. He earned his medical degree with distinction from The George Washington University and completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine.

Lifeward Ltd. reported first quarter 2026 revenue of $3.9 million, down from $5.0 million a year earlier, mainly due to lower AlterG shipments tied to working capital constraints. Gross margin fell to 34.2% from 42.2% on lower production volumes and higher tariffs.

GAAP net loss widened to $10.8 million or $6.70 per share, driven by a one-time, non-cash $4.9 million in-process R&D charge and other transaction-related expenses. On a non-GAAP basis, net loss was $5.1 million, similar to last year. Cash and cash equivalents rose to $11.4 million, helped by convertible note financing and $6.5 million of cash from the Oratech acquisition.

The company closed its strategic transaction with Oramed, completed a $10 million financing, acquired Oratech and upper body exoskeleton technology, and reduced quarterly operating cash burn by 33% year-over-year. Lifeward also disclosed it will delay filing its Form 10-Q for the quarter as it finalizes accounting for the March 2026 transaction.

Lifeward Ltd. has given notice that the employment of Jeannine Lynch, its Vice President of Strategy and Market Access, will be terminated effective May 3, 2026. The departure is being treated as a termination without cause under her Employment Agreement dated July 9, 2021.

Ms. Lynch will receive severance and other benefits in line with that Employment Agreement. The company previously described the terms of this agreement in its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 18, 2026.

Lifeward Ltd. reported that it has restored compliance with a key Nasdaq corporate governance rule. The company previously fell out of compliance with Nasdaq Listing Rule 5605(c)(2)(A) after director Hadar Levy resigned from the Board and its Audit Committee, leaving the committee below the required three members.

Nasdaq staff sent written notice on March 30, 2026, acknowledging the appointments of Moshe Rozenbaum, William Mark Sigsbee and Yehuda Reznick to the Audit Committee and confirming that Lifeward now meets the three-member requirement. Nasdaq stated the company is again in compliance with the rule and that the matter is closed.

Lifeward Ltd. completed its acquisition of Oratech Pharma in accordance with a prior share purchase agreement. At closing, it issued an aggregate 2,256,476 of its ordinary shares and pre-funded warrants, plus 1,296,296 additional warrants to Oramed and agreed to future revenue-sharing on ReWalk Personal Exoskeleton sales and related extended warranties.

To fund the transaction structure, Lifeward also issued $10,000,000 aggregate principal amount of senior secured convertible notes with accompanying warrants under an existing securities purchase agreement, in a private offering to accredited investors under Regulation D exemptions. Two Class II directors resigned without disagreement, and the board expanded from five to eight members with three new directors appointed and committee compositions updated.

Lifeward Ltd. reported that Nasdaq has notified the company it is no longer in compliance with the Nasdaq audit committee rule requiring at least three members. The non-compliance arose after director Hadar Levy resigned, leaving only two audit committee members.

The company is evaluating options to restore compliance within Nasdaq’s cure period, which runs until the earlier of its next annual shareholder meeting or February 24, 2027, subject to an August 24, 2026 deadline if the next annual meeting is held before that date. Lifeward’s ordinary shares will continue trading on the Nasdaq Capital Market under the symbol LFWD, and the notice has no immediate effect on the listing.

Lifeward Ltd. reported fourth quarter and full-year 2025 results while advancing a major strategic shift toward diversified biomedical innovation. Full-year 2025 revenue was $22.0 million, down from $25.7 million in 2024, but GAAP net loss narrowed to $19.9 million from $28.9 million as operating expenses fell 25%.

Fourth-quarter 2025 revenue was $5.1 million versus $7.5 million a year earlier, with lower AlterG and MyoCycle sales partly offset by stronger ReWalk exoskeleton revenue. Lifeward secured shareholder approval for a transformative Oramed transaction, under which Oramed may own up to 49.99% of Lifeward and provide up to $47 million in funding while contributing its POD™ oral protein delivery platform. The company also agreed to acquire a powered upper-body exoskeleton, targeting commercial launch in roughly 18–24 months. Cash and cash equivalents were $2.2 million as of December 31, 2025.

Lifeward Ltd. reported the results of its extraordinary shareholder meeting held on March 12, 2026. Shareholders representing 7,252,783 ordinary shares, about 39.7% of the 18,293,776 shares outstanding as of January 20, 2026, were present or voted, forming a quorum.

Investors approved issuing ordinary shares to Oramed Pharmaceuticals Inc. for the acquisition of 100% of Oratech Pharma, Inc., and related warrants and convertible note issuances tied to that deal. They also approved electing two external directors effective at the Oratech closing, their compensation framework, increasing shares under the 2025 Incentive Compensation Plan, and an equity grant to CEO Mark Grant.

Shareholders further approved reappointing Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent auditor for the year ending December 31, 2026, with the board authorized to set its remuneration.

Lifeward Ltd. reported that it has regained compliance with Nasdaq’s minimum bid price listing standard. The company received written notice from Nasdaq’s Listing Qualifications Hearings Department confirming that its Ordinary Shares met the $1.00 per share minimum closing bid price for 10 consecutive business days from February 24, 2026 to March 9, 2026. Nasdaq stated that the minimum bid price matter is now closed, meaning Lifeward’s Ordinary Shares continue to qualify for listing on the Nasdaq Capital Market.

Lifeward Ltd. implemented a 1-for-12 reverse share split of its ordinary shares effective February 24, 2026. The move is intended to help the company meet the $1.00 minimum bid price required to keep its Nasdaq Capital Market listing.

The reverse split reduced issued and outstanding ordinary shares from 18,339,098 to approximately 1,528,098, while the company’s authorized ordinary shares increased from 75,000,000 to 100,000,000 under its Eighth Amended and Restated Articles of Association. No fractional shares were issued, with holdings rounded down to the nearest whole share, and the shares now trade on a split-adjusted basis under the existing symbol LFWD.

Lifeward Ltd. reported a change in its Board of Directors. On February 24, 2026, Class I director Hadar Levy notified the Board of his decision to step down, effective the same day. The company stated that his departure was not due to any disagreement regarding operations, policies or practices, and expressed gratitude for his service and contributions.

Lifeward Ltd. entered into an Intellectual Property Assignment and Technology Transfer Agreement with Skelable Ltd. on February 19, 2026. Lifeward will acquire specified intellectual property and related technology assets and bring certain key Skelable employees on board under new employment agreements.

As consideration, Lifeward will pay up to $500,000 in three milestone-based installments, with $480,000 payable in ordinary shares and $20,000 in cash. The shares will be priced at the higher of the prior trading day’s closing price or the daily volume-weighted average price. These shares will be issued as an unregistered offering relying on the Section 4(a)(2) exemption under the Securities Act of 1933. The initial closing of the transaction is expected to occur in the near future, subject to customary conditions.

Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. for an initial principal amount of $525,000, which may be increased by up to an additional $975,000 upon mutual consent. This follows a prior secured promissory note for $3.0 million that remains outstanding.

The new note is secured by a lien on the company’s cash, carries interest at 24% per annum, and matures on the earlier of August 12, 2026 or the company’s failure to obtain shareholder approval for the transactions under the January 12, 2026 securities purchase and share purchase agreements. It includes customary covenants restricting additional indebtedness, liens, major transactions, and affiliate dealings, and defines standard events of default such as non-payment, covenant breaches, insolvency, and material adverse effects.

Upon default, Oramed may accelerate all obligations, increase the interest rate, terminate its commitments, and exercise contractual and legal remedies. Proceeds from the collateral will be applied ratably to Lifeward’s obligations under both the initial and subsequent secured promissory notes.

Lifeward Ltd. received an additional 180-day grace period from Nasdaq, until August 3, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company previously failed to meet this rule by the initial February 2, 2026 deadline.

Shareholders have already approved a reverse share split, and the board has set a 1-for-12 split ratio, with timing and implementation to be decided. Lifeward plans to monitor its share price and consider actions, including the approved reverse split, but notes there is no assurance it will regain compliance or avoid a potential delisting process.

Lifeward Ltd. filed a report outlining governance changes tied to its planned transaction with Oramed Pharmaceuticals. The company now expects its board to expand to eight members upon closing of the Share Purchase Agreement, with three directors designated by Lifeward, three by Oramed, and two serving as External Directors under Israeli law.

Lifeward also called an Extraordinary General Meeting for March 12, 2026, and filed a preliminary proxy statement. Shareholders will be asked to approve a private placement of ordinary shares that would give Oramed at least 45.00%, and potentially more than 49.99%, of Lifeward’s outstanding voting power, a structure that may be deemed a Nasdaq “change of control” and is described as exempt from Israel’s special tender offer rules.

Lifeward Ltd. entered into a share purchase agreement to acquire all equity of Oratech Pharma from Oramed Pharmaceuticals. At closing, Lifeward will issue Ordinary Shares and pre-funded warrants to Oramed equal to 49.99% of its fully diluted equity, with Ordinary Shares capped at 45.00% of outstanding shares immediately after closing and the balance in pre-funded warrants subject to a 49.99% beneficial ownership cap. Additional transaction warrants will be issued based on Lifeward’s net cash at closing at an exercise price of $0.45 per share.

The deal also includes revenue sharing payments to Oramed equal to 4% of net revenue from ReWalk Personal Exoskeleton products until the earliest of 10 years after closing, receipt of a contractually defined maximum amount, or when Lifeward’s market capitalization reaches $200 million. Concurrently, Lifeward agreed to issue up to $20,000,000.00 of senior secured convertible notes bearing 8.0% interest, convertible at $0.45 per share, plus accompanying warrants, all subject to shareholder approval and ownership caps at 49.99%.

Lifeward Ltd. (LFWD) entered a secured financing, issuing a Secured Promissory Note to Oramed for $3.0 million. The loan is secured by a lien on cash, bears 15% annual interest, and matures on May 14, 2026. The note includes customary covenants and default provisions and may require a $500,000 termination fee under certain circumstances.

The note is convertible at $0.45 per ordinary share, with a 4.99% beneficial ownership limit and mandatory conversion under certain circumstances. Separately, the company furnished a press release announcing Q3 2025 results and held a conference call on November 14, 2025 at 8:30 a.m. E.S.T., with an archived webcast available for 30 days.

Lifeward Ltd. (LFWD) reported preliminary, unaudited Q3 results for the quarter ended September 30, 2025. The company estimates revenue of approximately $6.2 million and U.S. GAAP operating expenses of about $5.8–$5.9 million for the period.

Liquidity at quarter-end was limited, with cash and cash equivalents of approximately $2.0 million as of September 30, 2025. The company also stated its cash, cash equivalent and short‑term investment balance was approximately $2.0 million as of the same date.

Management prepared these figures and they are subject to customary quarter-end close procedures, which could change the amounts. The company’s independent auditor, EY, has not audited, reviewed, or compiled these results. Actual results will appear in the upcoming Form 10‑Q. The information was furnished under Item 2.02 and is not deemed filed under the Exchange Act.

Lifeward Ltd. furnished a press release announcing its financial results for the second quarter ended June 30, 2025. The company will host a conference call to discuss those results at 8:30 a.m. E.D.T. on August 14, 2025, and an archived webcast will be available at the provided link and on the company’s Investors page for 30 days. The press release is furnished as Exhibit 99.1 and the cover page interactive XBRL is provided as Exhibit 104. The filing states these materials are furnished and are not to be deemed “filed” or incorporated by reference into other securities filings. The company’s ordinary shares trade under the LFWD ticker on the Nasdaq Capital Market.

Lifeward Ltd. appointed Almog Adar as its Chief Financial Officer, effective August 1, 2025. Mr. Adar, age 42, is an internal promotion from Vice President of Finance and Chief Accounting Officer and will continue as the company’s principal accounting officer.

His compensation package includes an annual base salary of $315,000, an annual performance bonus opportunity of up to 35% of base salary, a one-time retention payment of $80,000 (paid in two installments), eligibility for an additional prorated 7% bonus for 2025, and a grant of options to purchase 225,000 ordinary shares vesting in four equal annual installments. Termination protections include six months salary continuation (longer for a change of control), target bonus continuation, health premium reimbursement, and accelerated vesting on certain change-of-control terminations. The agreement includes non-solicitation, non-competition and indemnification provisions.

Lifeward Ltd. received a notification from The Nasdaq Stock Market that its closing bid price has been below the required minimum of $1.00 per share for the last 30 consecutive business days. The notice is a deficiency, not a delisting, and does not currently affect the listing or trading of the companys ordinary shares.

The company has 180 days to regain compliance, until February 2, 2026, by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Lifeward may be eligible for a second 180-day cure period if, as of that date, it has a market value of publicly held shares of at least $1 million, meets other initial listing standards except the bid price requirement, and provides written notice of its intent to cure.

Management states it will monitor the closing bid price and consider plans to regain compliance but expressly warns there is no assurance it will be able to do so within the cure period or any extension. The report includes customary forward-looking statements and refers readers to the companys SEC filings for additional risk factors.

Lifeward (Nasdaq: LFWD) filed an 8-K reporting entry into a Material Definitive Agreement for a best-efforts public offering that closed on 26 Jun 2025.

The company sold 4 million ordinary shares and 4 million five-year warrants at a combined $0.65, raising ~$2.0 million net after fees. H.C. Wainwright acted as placement agent, earning 8% in cash fees, expense reimbursements and 240,000 warrants exercisable at $0.8125.

The Purchase Agreement restricts additional share issuances for 30 days and bans variable-rate financings for one year, easing near-term dilution concerns. Proceeds will fund commercial expansion, working capital and general corporate purposes. The securities were registered on Form S-1 (File No. 333-288172) declared effective 25 Jun 2025.